10-K/A: Senti Biosciences Files Amended 10-K with Governance Details

Senti Biosciences Holdings, Inc. has filed an amendment to its 2025 annual report, providing detailed information on its directors, executive officers, corporate governance, and executive compensation.

Summary

• This filing is an amendment to Senti Biosciences Holdings, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• The amendment is being filed to include Part III information (Items 10, 11, 12, 13, and 14) because the company will not file its definitive proxy statement within the required timeframe.
• The filing details the company's directors, executive officers, board committees (Audit, Compensation, Nominating and Corporate Governance), and their respective responsibilities.
• It outlines the compensation structure for non-employee directors, including cash retainers and equity awards, as well as the compensation for named executive officers for the fiscal year 2025.
• Information regarding security ownership by directors, executive officers, and major shareholders is provided as of March 27, 2026.
• The document also discloses certain relationships and related party transactions, including details of a private placement (PIPE) and agreements with GeneFab, LLC.
• Principal accountant fees for KPMG LLP for the years 2025 and 2024 are listed.
• The filing includes updated certifications from the CEO and CFO regarding the accuracy and fairness of the report.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's an administrative amendment to provide required governance and compensation details due to a proxy statement delay, rather than a report on operational or financial performance.

Positives

• The company has a robust board structure with independent directors and established committees overseeing key areas like audit, compensation, and governance.
• Detailed disclosure of executive and director compensation aims to align with shareholder interests.
• The company has a clear policy on insider trading, pledging, and hedging of company stock.
• A compensation recovery policy is in place to address material noncompliance with financial reporting requirements.
• The company has a comprehensive Code of Business Conduct and Ethics applicable to all directors, officers, and employees.

Negatives

• The company is filing Part III information via an amendment because it will not file its proxy statement on time, indicating potential procedural or timing issues.
• The board leadership structure lacks a Chairperson and a lead independent director, with the CEO presiding over board and stockholder meetings.
• The company's financial statements and other financial information are presented in a separate filing, not directly within this amendment.

Risks

• The company's reliance on forward-looking statements means actual results could differ materially due to inherent risks and uncertainties.
• The potential for clawbacks of incentive-based compensation exists if financial statements require restatement due to material noncompliance.
• The company's insider trading policy prohibits various speculative transactions, limiting certain executive and director financial activities.

Future Outlook

The filing itself does not contain forward-looking financial guidance. It primarily focuses on corporate governance, executive and director compensation, and security ownership. Forward-looking statements are generally discussed in the context of the company's overall business strategy and operations, but specific financial projections are not detailed within this amendment.

Management Comments

• Jay Cross certifies that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading.
• Jay Cross certifies that the financial statements and other financial information included in the report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented.
• Timothy Lu, M.D., Ph.D. certifies that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading.
• Timothy Lu, M.D., Ph.D. certifies that the financial statements and other financial information included in the report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented.

Industry Context

StockSavvy.ai notes that this amended 10-K filing from Senti Biosciences, a company in the biotechnology sector, highlights the critical importance of transparent corporate governance and executive compensation disclosures, especially when proxy statements are delayed. Such filings are standard practice for companies to ensure compliance with SEC regulations while providing essential information to investors.

Comparison to Industry Standards

• The board composition, with a mix of scientific, financial, and business expertise (e.g., Dr. Timothy Lu, Edward Mathers, Frances Schulz, Donald Tang), aligns with typical structures in the biotechnology industry.
• The establishment of independent Audit, Compensation, and Nominating/Governance committees is a standard best practice across publicly traded companies, including those in the biotech sector.
• The compensation structure for non-employee directors, including cash retainers and equity awards, is comparable to industry norms, aiming to attract and retain qualified individuals.
• The company's adherence to Nasdaq listing rules for director independence is a benchmark for companies listed on major exchanges.

Corporate Governance

Related Party Transactions

• The Iyer Family Revocable Trust (associated with Kanya Rajangam) purchased Series A preferred stock and warrants in the December 2, 2024 PIPE.
• New Enterprise Associates 15, L.P. (affiliated with Edward Mathers) purchased Series A preferred stock and warrants in the December 2, 2024 PIPE.
• Bayer HealthCare LLC purchased Series A preferred stock and warrants in the December 2, 2024 PIPE.
• Celadon Partners SPV 24 (affiliated with Donald Tang) purchased Series A preferred stock and warrants in the December 2, 2024 PIPE.
• An agreement exists with GeneFab, LLC (managed by Celadon Partners, LLC) involving the sale of assets, a sublease, and a potential license agreement.
• A Development and Manufacturing Services Agreement (DMSA) is in place with GeneFab, with an advance payment made by Senti Biosciences.
• An Option Agreement grants GeneFab the right to invest up to $20.0 million in Senti Biosciences' common stock.
• Yvonne Li, former Interim CFO, has a consulting agreement with the company.
• James Collins, a director, has an agreement to serve as chair of the Scientific Advisory Board (SAB) with associated compensation and stock options.

Stakeholder Impact

• Shareholders: The filing provides transparency on governance and compensation, which can influence investor confidence. The PIPE transaction and potential future equity issuance via the Option Agreement could impact share dilution.
• Executive Officers and Directors: Details on compensation, equity awards, and severance benefits are provided, aligning their interests with the company's performance.
• Employees: The company's 401(k) plan and other benefits are available to employees, including executive officers.
• Suppliers/Service Providers: Agreements with entities like GeneFab for development and manufacturing services indicate ongoing operational relationships.

Next Steps

• The company will need to file its definitive proxy statement to fulfill regulatory requirements.
• The company will continue to manage its board and executive compensation structures as outlined.
• The company will proceed with any required stockholder approvals related to the Option Agreement with GeneFab.

Key Dates

Keywords

Senti Biosciences, 10-K Amendment, Corporate Governance, Executive Compensation, Director Compensation, Board of Directors, SEC Filing, Sarbanes-Oxley Act, Financial Reporting, Related Party Transactions